

**ibandronic acid (Bondronat®)**

**(No. 123/04)**

**Roche**

*Indication: Prevention of skeletal events in patients with breast cancer and metastatic bone disease*

## Summary of Advice

11 October 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following a full submission.

Ibandronic acid is accepted for use within NHS Scotland for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

It reduces the rate of skeletal events consisting of a composite of vertebral fractures, pathological non-vertebral fractures and the need for radiotherapy or surgery to deal with bone complications. It can be given both by the oral or intravenous route.

Professor David H Lawson  
Chairman